home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410n.zip
/
M94A2436.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
40 lines
Document 2436
DOCN M94A2436
TI Discordant evolution of HIV and HCV serologies in IVDUs: a four years
retrospective study.
DT 9412
AU Mansuy JM; Lheritier D; Puchot P; Puppo P; Gayet C; Izopet J; Puel J;
Laboratoire de Virologie, CHU Purpan, Toulouse, France.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):304 (abstract no. PC0147). Unique
Identifier : AIDSLINE ICA10/94370139
AB OBJECTIVES: To evaluate the course of HIV and HCV serological markers in
a IVDU population since 1990. METHODS: All patients were IVDUs before
the serological tests and were followed in a drug-weaning institution
(Centre L. Engelmejer/IDRET). HIV and HCV serologies were performed in
1417 subjects (1110 males, 307 females) by EIA methods. Positives
results were confirmed by an immunoblot (LAV Blot 1 Diagnostics Pasteur,
RIBA II, III Ortho Diagnostic System). Khi2 test was used for
statistical analysis. RESULTS: TABULAR DATA, SEE ABSTRACT SEE VOLUME.
Frequency of HIV positive serologies decreased (from 69.8% to 34.2%)
during follow up (p < 0.0001). In contrast, we observed a significant (p
= 0.009) increased of HCV positive serologies from 1990 to 1992.
Serologies performed in 1993 showed decrease (p = 0.002) of HCV
seroprevalence among the IVDUs studies. CONCLUSION: The decrease of HIV
seroprevalence among the population studied is an important fact. Such a
decrease may be correlated to a sudden awareness of the epidemiologic
risk by the IVDUs and to the recent measure of the French Department of
the Health (uncontrolled syringes released). The increase of the HCV+
population among IVDUs between 1990 and 1992 is dramatic. However, we
cannot exclude that this result could reflect higher sensibility of the
third generation diagnostic kits (since middle of the 92th). The HCV
seroprevalence increase was not confirmed in 1993, thus we suggest that
this evolution should be confirmed in the next years.
DE Female France/EPIDEMIOLOGY Hepatitis Antibodies/*ANALYSIS Hepatitis
C/EPIDEMIOLOGY/TRANSMISSION Hepatitis C Viruses/IMMUNOLOGY Human *HIV
Seropositivity HIV Seroprevalence Male Retrospective Studies
Substance Abuse, Intravenous/*COMPLICATIONS/IMMUNOLOGY MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).